Marvell Technology and Bausch Health are buying

Bausch Health: “We wanted to buy more today, but we ran out of time. This thing is being put up for sale. There are shorts that take it all the way down. It’s pretty ridiculous. I wanted to be able to buy a huge slug of it today, so that’s how I feel [Charitable Trust]. “
Accenture: “They smashed that stock. The business is fantastic. They had a great quarter. I tell people [buy, buy, buy]. “
Celularity: “It̵[ads1]7;s one of the higher risk stocks out there. The way I would look at it, be prepared to lose everything, but otherwise make a lot of money if it works out.”
Manulife: “They take too much risk, Manulife. I’m not there for the 5% [dividend yield]. I do not need it. Too much risk in the common stock. “
Marvell Technology: “You should [keep buying more of it]. This company has two businesses: high performance computing and 5G. We know that these are the two strongest areas. It has no PC business. It has no gameplay. Marvell is a stock that we have bought, bought, bought for Charitable Trust, and I think you should too. “
Iron Mountain: “I like Iron Mountain. Good returns, very consistent business. [Buy, buy, buy]. “
Disclosure: Cramer’s Charitable Trust owns shares in BHC and MRVL.
Register now for the CNBC Investing Club to follow Jim Cramers every move in the market.